See more : Compagnie Financière Richemont SA (0QMU.L) Income Statement Analysis – Financial Results
Complete financial analysis of Sunder Biomedical Tech. Co., Ltd. (4115.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sunder Biomedical Tech. Co., Ltd., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Merck & Co., Inc. (0QAH.L) Income Statement Analysis – Financial Results
- Annaly Capital Management, Inc. (NLY-PF) Income Statement Analysis – Financial Results
- Dinglong Culture Co., Ltd. (002502.SZ) Income Statement Analysis – Financial Results
- SPX Technologies, Inc. (SPXC) Income Statement Analysis – Financial Results
- Elite Color Environmental Resources Science & Technology Co., Ltd. (002998.SZ) Income Statement Analysis – Financial Results
Sunder Biomedical Tech. Co., Ltd. (4115.TWO)
About Sunder Biomedical Tech. Co., Ltd.
Sunder Biomedical Tech. Co., Ltd. manufactures and sells medical devices. It offers protective goggles, melt blown nonwoven fabric and mask, suction irrigation set, smoke filter, endo bag, blood line set for hemodialysis, A.V. Fistula needle set, I.V. administration, extension tube, volume control I.V. administration set, surgical tubing set, components, and transducer protector, as well as PVC compounds for medical applications. The company was founded in 1998 and is based in Taichung, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 770.19M | 1.05B | 1.14B | 910.65M | 0.00 |
| Cost of Revenue | 692.28M | 913.03M | 938.83M | 744.42M | 0.00 |
| Gross Profit | 77.91M | 140.52M | 200.78M | 166.23M | 0.00 |
| Gross Profit Ratio | 10.12% | 13.34% | 17.62% | 18.25% | 0.00% |
| Research & Development | 29.44M | 29.32M | 25.63M | 26.60M | 0.00 |
| General & Administrative | 55.21M | 58.17M | 58.18M | 49.18M | 0.00 |
| Selling & Marketing | 30.68M | 37.51M | 36.06M | 27.63M | 0.00 |
| SG&A | 85.89M | 95.67M | 94.25M | 76.80M | 0.00 |
| Other Expenses | 0.00 | 5.90M | 14.88M | 5.73M | 0.00 |
| Operating Expenses | 77.91M | 124.99M | 119.87M | 103.40M | 0.00 |
| Cost & Expenses | 807.60M | 1.04B | 1.06B | 847.82M | 0.00 |
| Interest Income | 2.58M | 1.29M | 1.22M | 776.00K | 741.00K |
| Interest Expense | 12.51M | 10.77M | 9.19M | 9.87M | 11.36M |
| Depreciation & Amortization | 104.62M | 104.50M | 96.43M | 85.84M | 0.00 |
| EBITDA | 76.61M | 127.49M | 193.39M | 154.82M | 107.18M |
| EBITDA Ratio | 9.95% | 12.07% | 16.97% | 17.04% | 0.00% |
| Operating Income | -28.05M | 22.72M | 97.01M | 69.33M | 0.00 |
| Operating Income Ratio | -3.64% | 2.16% | 8.51% | 7.61% | 0.00% |
| Total Other Income/Expenses | -12.47M | -3.57M | 6.92M | -3.36M | -12.55M |
| Income Before Tax | -40.52M | 12.23M | 87.77M | 59.10M | 0.00 |
| Income Before Tax Ratio | -5.26% | 1.16% | 7.70% | 6.49% | 0.00% |
| Income Tax Expense | -7.36M | -1.09M | 16.72M | 6.52M | -13.72M |
| Net Income | -33.16M | 13.32M | 71.06M | 52.58M | 13.72M |
| Net Income Ratio | -4.30% | 1.26% | 6.24% | 5.77% | 0.00% |
| EPS | -0.55 | 0.22 | 1.18 | 0.88 | 0.23 |
| EPS Diluted | -0.55 | 0.22 | 1.18 | 0.87 | 0.23 |
| Weighted Avg Shares Out | 60.00M | 60.00M | 60.00M | 60.00M | 59.65M |
| Weighted Avg Shares Out (Dil) | 60.00M | 60.06M | 60.17M | 60.14M | 59.65M |
Source: https://incomestatements.info
Category: Stock Reports